Skip to main content
. 2020 Sep 21;11(11):3289–3298. doi: 10.1111/1759-7714.13670

Figure 3.

Figure 3

HCC827/GR enhanced the migration of macrophages via CCL2. (a) The transcription of CD206 in THP‐1/M2 after induction by PMA and IL‐4, P = 0.0005. (b) The protein expression of CD206 tested by western blot in THP‐1/M2 after induction by PMA and IL‐4. (c) The transcription of IL‐10 in THP‐1/M2 after induction by PMA and IL‐4, P < 0.0001. (d and e) Transwell migration assay image and assay data confirmed that the migration ability of HCC827 treated with CCL2 recombinant protein was significantly higher than that of HCC827 with dose‐dependence, HCC827 vs. Re‐CCL2 (10 ng/mL) = 52 ± 7.21 vs. 65.67 ± 1.53, P = 0.0325; HCC827 vs. Re‐CCL2 (100 ng/mL) = 52 ± 7.21 vs. 84.67 ± 10.02, P = 0.0102. (f and g) Transwell migration assay image and assay data confirmed that the migration ability of HCC827/GR treatment with CCL2 blocking antibodies was significantly lower than that of HCC827/GR with dose‐dependence, HCC827/GR versus anti‐CCL2(1 μg/mL) = 95 ± 9.0 versus 79.33 ± 3.21, P = 0.0469, HCC827/GR versus anti‐CCL2 (10 μg/mL) = 95 ± 9 versus 55.33 ± 9.29, P = 0.006. Scale bar, 200 μm.